With that in mind, let's consider two stocks that haven't performed well recently and are now near their 52-week lows but that are still worth investing in: CRISPR Therapeutics (NASDAQ: CRSP) and ...
Genetic changes are a significant cause of infertility, impacting over 15% of the global population. TLE6, a major protein ...
MarketBeat on MSN3h
Vertex's Pain Drug: Big Pharma's Next Major Success?Vertex Pharmaceuticals (NASDAQ: VRTX) is a biotechnology company with a strong track record of success in developing ...
Our writer thinks these two speculative shares offer high long-term growth potential from where they currently sit in the ...
"Programs like AIM are essential to not only driving startups’ innovation journey but also reinforcing UC San Diego's role as ...
But, no matter what direction the general market takes, some stocks could stand out, potentially in 2025, and most ...
ErlySign’s innovation is a biomarker-based test kit capable of detecting oral precancerous conditions within just 15 minutes ...
10h
Bengaluru-based biotechnology startup, CrisprBits Private Limited, has inaugurated a CRISPR gene editing and diagnostics ...
Recent TAU study demonstrates how a crucial but underexplored process of DNA transfer between bacteria affects its defense ...
For years, attempts have been made to cure type 1 diabetes, in which sufferers are dependent on insulin injections as soon as ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback